1-(Prop-2-en-1-yl)piperazin-2-one | 59702-24-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(Prop-2-en-1-yl)piperazin-2-one
• 英文别名: 1-prop-2-enylpiperazin-2-one
• CAS: 59702-24-8
• 化学式: C₇H₁₂N₂O
• mdl: MFCD06803964
• 分子量: 140.18
• InChiKey: MZQXOPAXYJPKIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  tert-butyl 4-propenyl-3-oxopiperazine-1-carboxylate 、 盐酸 以 乙酸乙酯 为溶剂， 反应 1.67h， 生成 、 1-(Prop-2-en-1-yl)piperazin-2-one
  参考文献：
  名称：

  Hiv Integrase Inhibitors

  摘要：

  双环尿嘧啶及相关化合物是HIV整合酶抑制剂和HIV复制抑制剂。在一种实施例中，这些化合物为I式：其中a、b、Y、R1、R2、R3和R4的定义如本文所述。这些化合物在预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病方面非常有用。这些化合物可作为化合物本身或以药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为药物组合物的成分，可选地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。

  公开号：

  US20080009490A1

文献信息

• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE L'INTEGRASE DU VIH
  申请人：MERCK & CO INC

  公开号：WO2005092099A1

  公开（公告）日：2005-10-06

  Bicyclic uracils and related compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the compounds are of Formula (I) wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  双环尿嘧啶及相关化合物是HIV整合酶的抑制剂，也是HIV复制的抑制剂。在一个实施例中，这些化合物符合以下式（I）的定义，其中a、b、Y、R1、R2、R3和R4在此处被定义。这些化合物对预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病具有用处。这些化合物可作为化合物本身或作为药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为药物组合物中的成分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER
  申请人：Weber Lutz

  公开号：US20090068144A1

  公开（公告）日：2009-03-12

  The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections.

  本发明提供了一种化合物，所述化合物选择自式I的化合物作为配体与HDM2蛋白结合，诱导细胞凋亡和抑制增殖，并在癌症治疗中具有治疗用途。式（I）的化合物可用作治疗中风、心肌梗死、缺血、多器官衰竭、脊髓损伤、阿尔茨海默病、缺血事件引起的损伤、心脏瓣膜退行性疾病的治疗剂。此外，式（I）的化合物可用于减少细胞毒性癌症药物的副作用和治疗病毒感染。
• NOVEL TETRAHYDRO-ISOQUINOLINES
  申请人：Weber Lutz

  公开号：US20090306130A1

  公开（公告）日：2009-12-10

  The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

  本发明提供了一种化合物，选择自式（A）的化合物作为配体与HDM2蛋白结合，诱导细胞凋亡和抑制增殖，并在癌症治疗和预防中具有治疗用途。式（A）的化合物可用作治疗中风、心肌梗死、缺血、多器官衰竭、脊髓损伤、阿尔茨海默病、缺血事件和心脏瓣膜退行性疾病的治疗剂。此外，式（A）的化合物可用于减少细胞毒性癌症药物、辐射的副作用，并用于治疗病毒感染。
• HIV integrase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US07820680B2

  公开（公告）日：2010-10-26

  Bicyclic uracils and related compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the compounds are of Formula I: wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  双环尿嘧啶及相关化合物是HIV整合酶的抑制剂和HIV复制的抑制剂。在一种实施例中，该化合物具有公式I： 其中a、b、Y、R1、R2、R3和R4的定义如本文所述。该化合物对预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病具有用处。该化合物可作为化合物本身或以药学上可接受的盐的形式用于对抗HIV感染和艾滋病。该化合物及其盐可作为制药组合物的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Selnick Harold G.

  公开号：US20110021516A1

  公开（公告）日：2011-01-27

  The present invention is directed to compounds of the formula (I): (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , G 1 , G 2 , G 3 , G 4 , J, Q, E a , E b , E c , R 6 , R 7 , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式(I)的化合物：（其中变量A1、A2、A3、A4、A5、A6、A7、A8、G1、G2、G3、G4、J、Q、Ea、Eb、Ec、R6、R7、RPG和Y如本文所述），它们是CGRP受体拮抗剂，并且在治疗或预防CGRP参与的疾病，如偏头痛中有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。